{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "To assess whether apixaban is non-inferior to dalteparin for the treatment of cancer-associated VTE, with a focus on benefit-risk profile regarding VTE recurrence and major bleeding.",
    "target_disease": "cancer-associated venous thromboembolism (VTE)",
    "type_of_randomization": "",
    "randomization_stratification": [
        "cancer localization (e.g., GI, genitourinary, gynecological, lung)"
    ],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "Incidence of recurrent VTE at 6 months.",
    "secondary_efficacy_outcomes": [
        "Rates of recurrent VTE in subgroups based on cancer type (gynecological, GI, genitourinary, lung)"
    ],
    "primary_safety_outcome": "Major bleeding.",
    "secondary_safety_outcomes": [
        "Composite of major and clinically relevant non-major (CRNM) bleeding",
        "All bleeding events"
    ],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}